We have developed a general expression system that enhances the production and secretion of proteins in mammalian cells. The protein of interest is expressed as a fusion to a signal peptide and the Fc fragment of immunoglobulin as the N-terminal fusion partner, which can direct the cellular processes into expressing and secreting high levels of many different types of proteins. These include secretory proteins, enzymes and soluble domains of membrane proteins, as well as nuclear and regulatory proteins. Typical expression levels of these proteins from stable cell lines ranged from several to 100 µg/ml in conditioned media. The Fc domain helps to solubilize hydrophobic proteins and provides a handle for easy detection and purification of the fusion proteins; and it can be cleaved off by treatment with protease if desired.
Introduction
Expression systems employing gene fusion constructs are commonly used to enhance the production of proteins in bacteria. Using a bacterial protein that is normally expressed at high levels as the N-terminal fusion partner can help to ensure efficient transcription and translation of the message, and in some cases the secretion and solubilization of the fusion protein (Smith and Johnson, 1988; Hopp et al.,1988; LaVallie et al., 1993a) .
The major purpose of expressing recombinant fusion proteins in mammalian cells has been to confer novel properties to these hybrid molecules. This includes the specific targeting of a cytokine or toxin in vivo, Fc receptor binding, complement fixation, protein A binding, increasing the half-life and crossing the blood-brain barrier. Examples include the antibody-cytokine fusion proteins (Gillies et al., 1992 (Gillies et al., , 1993 , immunoadhesins (Capon et al., 1989) , immunotoxins (Chaudhary et al., 1989) and a nerve growth factor conjugate (Friden et al., 1993) .
With the advent of rapid gene identification through the human genome project and expressed sequence tags (Adams et al., 1991) , there is an urgent need for an equally rapid technology to produce and purify the gene products to aid in the identification of gene function. Most of these gene products are complex human proteins that should be best expressed in mammalian cells to preserve the correct folding and posttranslational modifications.
We found that a gene fusion construct consisting of DNA fragments encoding a signal peptide, the Fc fragment of the immunoglobulin γ gene (human γ-1 or murine γ-2a), followed by the protein of interest, facilitates efficient production and secretion of many different categories of proteins. For proteins that are normally secreted, this technology can increase the expression level many-fold. For non-secretory proteins, such as nuclear proteins and regulatory proteins, and some hard to express proteins, the overexpression of which may be toxic to the host cell, this technology enhances expression because the protein product is secreted. Furthermore, the Fc, which is glycosylated and highly charged at neutral pH, helps to solubilize hydrophobic proteins. Secretion of the fusion protein alleviates the toxicity inside the cell and permits the isolation of stable production cell lines. The fusion protein products in the culture media can be readily assayed and purified by a common set of reagents. In addition, the protein of interest in the fusion protein retains its native conformation, and biological and enzymatic activities. If desired, the protein can be isolated in pure form by a simple cleavage procedure.
Materials and methods

Construction of signal peptide-Fc
The N-terminal partner used in our human Fc fusion construct is the signal peptide followed by the human Fcγl. The plasmid construction is described in Figure 1 . The genomic DNA sequence encoding the signal peptide for the light chain of a murine antibody (Gillies et al., 1989) was modified as an XbaI-AflII fragment of about 450 base pairs (bp). Specifically an XbaI site was introduced 5Ј of the translation initiation codon and the consensus sequence for optimal ribosome binding (Kozak et al., 1984) . At the 3Ј end, the gene sequence encoding the -2 amino acid residue (-1 amino acid being the C-terminus of the signal peptide) of the signal peptide was mutagenized from a serine to a leucine (AGC to TTA) so that the DNA encoding the end of the signal peptide is CTTAAGC. Such a mutation created an AflII site.
The genomic DNA sequence encoding the human Fc was mutagenized by performing a PCR using a 5Ј sense primer with the following sequence: GAGAATTCTTAAGCGAGC-CCAAATCTTCTGACAAAACTCAC. This primer introduced an AflII site (underlined) and a cysteine to serine mutation (TGT to TCT, bold). The cysteine being mutated is the one that is normally involved in disulphide bonding with the light chain.
There is a XmaI restriction site located 280 bp upstream of the translation stop codon in the DNA sequence encoding the human Cγ1. This XmaI site was destroyed by introducing a silent mutation (TCC to TCA). Another silent mutation was introduced 10 bp upstream of the stop codon to create CCCCGGGTAAA(STOP), which contains a unique XmaI site. A muFc version with a unique XmaI site was also constructed with the murine Cγ2a cDNA.
The XbaI-AflII restriction fragment encoding the signal peptide was then ligated to the AflII-XmaI restriction fragment encoding the Fc. The resultant XbaI-XmaI restriction fragment therefore encodes the N-terminal fusion protein partner, and the gene encoding the protein of interest can be ligated via the XmaI site.
The expression vector is pdCs, in which the transcription of the Fc-X gene utilizes the enhancer/promoter of the human cytomegalovirus and the SV40 polyadenylation signal. The vector also contains the mutant dihydrofolate reductase gene (Simonsen and Levinson, 1983 ) as a selection marker.
Construction of the cassette containing the gene of interest
The gene of interest was constructed as an XmaI-XhoI restriction fragment. The XhoI restriction site could be introduced downstream of the translation stop codon either by PCR or by linker ligation. The XmaI site was introduced via a linkeradaptor. For example, the sequence of the linker-adaptor for CD26 was:
The first three codons in the top strand encode the last three amino acid residues of the CH3 domain, and starting with the codon GGC is the gene sequence of the extracellular domain of CD26. The linker-adaptor had the blunt end of a PvuII site, which was a convenient site for reconstruction with the rest of the CD26 cDNA. The lysine codon (in parenthesis) in the linker-adaptor is optional and it provides a cleavage site by enzymes such as trypsin or plasmin. Alternatively, for more specific proteolytic cleavage by enterokinase K, the gene sequence encoding the cleavage site was introduced via the following linker-adaptor:
CA AGT CCC CTA CTG CTA CTG CTA TTC GA
The nucleotides in bold encode the amino acid residues (Asp) 4 -Lys, the recognition site of enterokinase K. The linker-adaptor ends with a HindIII site, to which the gene of interest is joined.
Cell culture and transfection
Mouse myeloma NS/0 or hybridoma Sp2/0 Agl4 cells were transfected by electroporation or protoplast fusion and selected 496 in Dulbecco's modified Eagle's medium (Life Technologies) containing 10% fetal bovine serum and 100 nM methotrexate (Lo and Gillies, 1991) . Transfectants secreting Fc-X were identified by antiFc ELISA (Gillies et al., 1989) . Established clones could also be propagated in Hybridoma Serum Free Medium (Life Technologies), which simplifies purification. For transient expression, human kidney 293 cells were transfected with a coprecipitate of plasmid DNA and calcium phosphate (Sambrook et al., 1989) . Activity assays IL-2 activity of Fc-IL2 was assayed in standard T-cell proliferation assays as previously described (Gillies et al., 1992) . IL-4 activity of Fc-IL4 was assayed by measuring the proliferation response of PBMCs (Yokota et al., 1986) . IL-10 activity of Fc-IL10 was assayed by measuring the inhibition of cytokine (IL-12 and IFN-γ) synthesis by murine Th1 cells (Vieira et al., 1991) .
DPPIV enzyme activity was assayed (Tanaka et al., 1993 ) using glycylproline p-nitroanilide tosylate (Gly-Pro-pNA) as a substrate.
NAALADase activity was measured using the neuropeptide N-acetylaspartylglutamate as substrate (Carter et al., 1996) .
Characterization and purification of Fc-X fusion proteins
For routine characterization by gel electrophoresis, Fc-X fusion proteins in the conditioned media were first captured on Protein A Sepharose (Repligen) and then eluted by boiling in the protein sample buffer with or without 2-mercaptoethanol. After electrophoresis on an SDS gel, the protein bands were visualized by Coomassie staining.
For purification, the Fc-X fusion proteins bound on Protein A Sepharose were eluted in a sodium citrate buffer (100 mM, pH 4). The eluate was then immediately neutralized with 0.1 volume of 1 M Tris-HCl, pH 8. In the case of Fc-CD26, it was shown that such an elution procedure resulted in greater than 80% recovery of the Fc-CD26 with no loss of DPPIV activity.
Results
Vector construction
The secretion cassette (Figure 1 ) consists of a leader sequence derived from a variable region gene of a mouse kappa chain, fused to a DNA fragment encoding the hinge, CH2 and CH3 domains (collectively called the Fcγ1 or Fc) of the human immunoglobulin gamma-1 gene. A unique XmaI site was created by introducing a silent mutation 10 bp upstream of the stop codon. The DNA encoding the mature target protein is ligated in-frame to the XmaI site through the use of a linkeradaptor. The linker-adaptor can encode a proteolytic cleavage site for subsequent use in cleaving the target protein from the secretion cassette. For example, the linker-adaptor can encode a lysine residue at the junction of the fusion protein, which provides the option of cleaving the target protein from the Fc domain by plasmin or trypsin (Gillies et al., 1993) . Similarly, the linker-adaptor can encode the specific cleavage site of enterokinase (LaVallie et al., 1993b ) (Asp-Asp-Asp-Asp-Lys).
The expression vector is pdCs-huFc-X (Figure 1) , in which the transcription of the Fc-X DNA is placed under the control of the enhancer and promoter of the human cytomegalovirus. A similar version, pdCs-muFc-X, was also constructed in which the Fc of the murine IgGγ2a replaced the Fc of the human IgGγ1. Expression levels were determined by antiFc ELISA of conditioned media. For membrane proteins, cDNA encoding only the soluble portion was used in the fusion construct. Expression levels of Fc-oligopeptides ranged from 20 to 200 µg/ml depending on the nature of the peptides.
Production of Fc-X fusion proteins
Transient transfection of 293 cells were often used to check for correct construction and secretion of the Fc-X fusion proteins. Typical expression levels range from 200 to 1000 ng/ml in conditioned media 3-4 days post-transfection. Stable clones were obtained by transfection of Sp2/0, NS/0 or 293 cells and selection in media containing methotrexate. The expression levels of a number of proteins expressed as Fc-X are listed in Table I . The protein products in the conditioned media were purified in a single step by binding to Protein A Sepharose and analyzed by SDS gel electrophoresis followed by Coomassie staining (Figure 2 ), or by Western blot analysis, if necessary. Fc-X proteins were produced as homodimers, presumably through disulphide bonding in the hinge domain of the Fc. For example, Fc-PSA (human or murine Fc) gave a band of molecular weight 60 kDa under reducing conditions and a band of 110 kDa under non-reducing conditions (Figure 2) . Site-specific proteolytic release of Fc from Fc-X Often it is desirable to have the pure target protein without the Fc domain. Figure 3A shows the site specific cleavage by trypsin at the lysine residue introduced between Fc and soluble CD26. Fc-Lys-CD26 bound on Protein A Sepharose was cleaved by trypsin to release a protein of molecular weight 110 kDa, which corresponds to the size of the extracellular domain of CD26. As a control, Fc-CD26 without the lysine residue was similarly treated, and no CD26 was found to be released into the supernatant by trypsin. The results from the gel electrophoresis experiment were confirmed by dipeptidylpeptidase IV (DPPIV) (Tanaka et al., 1996) activity assays of the tryptic digests. Quantitative recovery of the DPPIV enzymatic activity was obtained in the supernatant when the Fc(Lys)CD26-bound Protein A Sepharose was treated with trypsin. In the parallel experiment with Fc-CD26, there was no DPPIV activity in the supernatant.
Cleavage of Fc-(Asp) 4 -Lys-gp120 by enterokinase and Fc- Lys-PSMA by plasmin are shown in Figure 3B and C, respectively.
Biological activities of Fc-X proteins
Cytokines expressed as Fc-X retain full activities in biological assays. For example, when compared with recombinant IL-2, IL-4 and IL-10, their Fc-X counterparts showed similar biological activities on a molar basis, within the accuracy of the assays. Because of the ease of production and purification, we use Fc-IL2 routinely to grow T cells. Most enzymes expressed as Fc-X also retain full enzymatic activity. For example, CD26 is also known as DPPIV, an exopeptidase. The CD26 moiety in Fc-CD26 was determined to be fully active, with K m ϭ 110 mM and V max ϭ 98 mM/ min/ml, which are similar to those of the native CD26 (180 mM and 82 mM/min/ml, respectively) (Tanaka et al., 1996) . Furthermore, the enzymatic activity of Fc-CD26 was inhibited by known peptide inhibitors IPI, VPL and APL, in a dosedependent manner, whereas non-inhibitor peptides such as GGG had no effect.
PSMA was recently demonstrated to have the substrate and pharmacological characteristics of a neuropeptidase known as NAALADase (Carter et al., 1993) . Purified Fc-PSMA had a specific NAALADase activity of 70-130 nmol/mg/min, compared with the 1.2 nmol/mg/min of a PSMA-rich membrane fraction reported by Carter et al. (Carter et al., 1993) .
Protein ligands or soluble receptors expressed as Fc-X retain their ligand-receptor binding affinities. For example, in the IL-4-IL4-R competitive binding assay, Fc-IL4R was used to coat ELISA plates; we found that Fc-IL4 competed well with 125 I-IL-4 on a equimolar basis. Similarly, there is no noticeable difference between Fc-gp120 and the recombinant gp120 in their binding to soluble CD4 (data not shown).
We also tested whether this technology could be used for the expression of Tat, a regulatory protein encoded by HIV (56 kDa) and light chain (31 kDa) of the bovine immunoglobulin from the growth medium could also be seen. In the middle lane, Fc(Lys)-CD26 bound on Protein A-Sepharose was incubated with a 1% trypsin solution at 37°C for 2 h. Trypsin inhibitor (Sigma) was then added to stop any further digestion. The supernatant was then removed and analyzed on an SDS gel. After Coomassie staining, a band having a molecular weight of 110 kDa, which corresponds to the size of CD26, was obtained. Fc-CD26 (without the lysine residue at the junction of the fusion) bound on Protein A-Sepharose was similarly treated, and CD26 was not released (left lane). (B) Purified Fc-(Asp) 4 -Lys-gp120 was digested with enterokinase (eK) to release gp120. The digestion was analyzed by SDS gel electrophoresis. Fc-(Asp) 4 -Lysgp120 has a molecular weight of about 150 kDa under reducing conditions. (C) Western analysis using polyclonal antisera raised against muFc-PSMA. Antisera against PSMA was generated by immunizing Balb/c mice with muFc-PSMA fusion protein. The polyclonal antisera (1:2000 dilution) was used to probe the PSMA protein by Western blot transfer. We used the huFc-PSMA for analysis because the muFc part of the muFc-PSMA would be recognized by the secondary anti-murine antibody. HuFc-PSMA was cleaved by plasmin to give huFc and PSMA (molecular weight of 36 and 100 kDa respectively, under reducing conditions); and PSMA was also susceptible to plasmin digestion to give smaller fragments. Only huFc-PSMA and its plasmin cleavage products were detected by the polyclonal antisera. The human Fc fragment was not detected.
that normally translocates to the nucleus. Fc-Tat was expressed as a 48 kDa protein, which was confirmed by Western blotting with an anti-Tat antibody. Fc-Tat was shown to be active, despite its fusion to the Fc, by the following transient expression experiment in 293 cells (Table II) . The expression vector for Fc-Tat (pdCs-FcTat) was cotransfected with a separate vector containing LTR-TAR-Kappa. As shown in Table II , high levels of expression and secretion of both Fc-Tat and Kappa were observed in the cotransfection with pdCs-Fc-Tat and LTR-TAR-Kappa. Transactivation of Kappa by Tat was also seen in the positive control, where pCEP-Tat was used; and little or no expression of Kappa was seen in the negative control, where there was no Tat. Therefore, the Kappa light chain is expressed only through transactivation of the LTR-TAR region by a functional Tat protein. These data suggest that the fusion protein can still traffic to the nucleus and function as a transactivator although most of the protein is secreted from the cell. Human 293 cells were transiently transfected with the different constructs as shown. The expression vector for Fc-Tat is pdCs-FcTat, as described in the text. LTR-TAR is the long terminal repeat DNA sequence (of HIV) that can be transactivated by the Tat protein, and Kappa is the gene sequence encoding the Kappa immunoglobulin light chain. The Tat protein was expressed using pCEP (Invitrogen) as a positive control for the transactivation of LTR-TAR-Kappa by Tat. To measure expression levels of Fc-Tat and Kappa, the conditioned media were assayed by anti-Fc and antiKappa ELISA respectively. 
Generation of murine antibody against muFc-X
An Fc-X expression vector using the mouse Fcγ2a was constructed to express fusion proteins that could be used to immunize mice. Since the Fc would be a self-antigen, the majority of the immune response should be directed to the fused protein. We used this approach to raise antibodies against the human prostate specific membrane antigen (PSMA). Purified muFc-PSMA (with adjuvant) was used to immunize mice. The antisera was shown to recognize PSMA by PSMA ELISA and Western blot analysis ( Figure 3C) . Spleen cells could then be used for fusion to generate hybridoma clones.
Glycosylation patterns
In some cases, the use of Fc as the N-terminal partner appears to direct the fusion protein to the ER-Golgi in a way that leads to more uniform glycosylation pattern. Such proteins may be useful in applications such as X-ray crystallography. As seen in Figure 4 , IL4-Fc was expressed as two distinct molecular species differing in N-glycosylation, since treatment with N-glycosidase resulted in a single discrete band having the expected molecular weight. On the other hand, Fc-IL4 was expressed as one single band when analyzed on an SDS gel, showing that its glycosylation is more uniform than that of IL4-Fc. In the case of soluble IL-4R, both IL4R-Fc and Fc-IL4R appeared as diffused bands on SDS gel, because of their multiple N-glycosylation sites. Treatment with N-glycosidase resulted in a single discrete band having the expected molecular weight.
Discussion
We have shown that the use of a signal peptide-Fc as an N-terminal fusion partner can 'fool' the cellular processes to express and secrete many different types of proteins at a high level. This gene fusion approach should be superior to an X-Fc construct, because X varies from case to case and may not be a protein that is normally targeted to the endoplasmic reticulum or capable of being expressed at a high level. On the other hand, the use of Fc at the N-terminus together with optimized translation initiation and secretory signals ensure that the Fc-X is directed efficiently through the secretory pathway. For example, while we obtained a high level of Fc gp-120 from transfected 293 cells, we did not have similar success with gp120-Fc.
The levels of fusion proteins secreted into the media were unexpectedly high for many proteins we have tested (Table I) . For example, Fc-IL2 accumulated in the culture media of the stably transfected cells at a level that was about 100-fold that which could be achieved with IL-2 using an equivalent vector without Fc. High expression levels were also obtained for Fc-IL4 and Fc-IL10, and all of the fused cytokines tested retained their biological activities. As in the case of immunoadhesins (Capon et al., 1989) , Fc fusion also confers a longer half-life. For example, Fc-IL10 has a serum half-life of 31 h (data not shown), which is the same as that of IL10-Fc (Zheng et al., 1995) , and much longer than the 30 min half-life of IL-10 (Gerard et al., 1993) .
We demonstrated that the Fc-X fusion approach worked well for proteins that are difficult to express otherwise. As illustrated by CD26, PSA and PSMA, the fused protein can be a protease that may be deleterious to the host cell. Thus, by efficiently exporting the protease outside the cell in the form of an Fc-X fusion, a higher level of expression can be achieved. Our approach should be particularly suited for the expression of the soluble form of a type II membrane protein such as CD26, since the C-terminus of CD26 in the Fc-X is free, as in the native protein. We should be able to expand our technology to the expression of other proteases and enzymes since the Fc-X fusion proteins tested preserve their enzymatic activities. Thus this approach is amenable to high throughput assays to screen for enzyme inhibitors.
The ease with which biologically active protein ligands and soluble receptors can be produced also greatly expedite our drug screening efforts of small molecule inhibitors of, for example, IL-4-IL-4 receptor, IgE-IgE receptor, NGF-TrkA and CD4-gp120 interactions. The use of Fc-X proteins offers an added advantage when used to coat ELISA plates. Presumably the Fc portion of the molecule, with an abundance of positive charged amino acid residues, binds preferentially to the ELISA plate, leaving the X moiety free to interact with the ligand in the subsequent binding step. On the other hand, if just X is used, some of the X coated on the plate may not have its binding site available. We have found consistently that we can coat plates with Fc-X at one-fifth the concentration of that of X alone, and obtain comparable results. This increase 499 in binding could also be attributed to avidity because there are two X moieties in an FcX molecule.
Our technology can be applied further to the expression of regulatory proteins such as transcription factors, which normally traffic to the nucleus. Regulatory proteins are generally difficult to express and the purification procedures cumbersome (Meisterernst et al., 1991) . Therefore, it is especially desirable that a method can be found to export such proteins into the culture medium. To demonstrate this, we made Fc-X fusion constructs of Tat, Rev and Nef, which are regulatory proteins encoded by HIV. We obtained high level expression and secretion of these fusion proteins, which were readily purified in a single step.
The use of murine Fc facilitates the use of Fc-X to immunize mice for the generation of antibodies, since the murine Fc region should not be immunogenic in the host animal. The availability of both the huFc-and muFc-X also makes the subsequent analysis of antibodies by ELISA and Western blot easier. Using this approach, we have successfully generated monoclonal antibodies against antigens such as PSMA (unpublished results) .
This general method of achieving high level expression of proteins should expedite the identification of gene function in the human genome project and EST sequences. In addition, the ability to rapidly express protein domains, such as SH2, should help in the understanding of domain functions, proteinprotein interactions and signal transduction.
